Ivan Buzurovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ivan Buzurovic has a total of 547 co-authors. Here are the top co-authors by number of shared publications:
Robert A. Cormack
Harvard Medical School
48 shared publicationsPhillip M. Devlin
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
43 shared publicationsMandar S. Bhagwat
28 shared publicationsThomas C. Harris
25 shared publicationsYan Yu
21 shared publicationsDesmond A. O'FArrell
20 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 25
A Novel Adjustable Tandem and Ring Applicator for Improved Dosimetry in Cervical Cancer HDR Brachytherapy
Introduction: Cervical cancer brachytherapy requires highly conformal dose delivery while minimizing radiation exposure to surrounding organs at risk. However, conventional tandem and ring applicators are limited by fixed geometry that may not optimally accommodate patient-specific anatomy. The purpose of this work was to evaluate the dosimetric performance of a novel tandem and ring applicator (RTA) featuring adjustable tandem translation relative to the ring, intended to improve organ-at-risk (OAR) sparing while preserving target coverage in high-dose-rate (HDR) brachytherapy for cervical cancer. Methods and Materials: A novel RTA allowing linear tandem translation within the ring plane was developed to enable patient-specific alignment without altering ring position. Two cervical cancer patients treated with external beam radiotherapy (45Gy/25 fractions) followed by HDR brachytherapy (27.5Gy/5 fractions) were analyzed. Conventional and novel RTAs were sequentially applied to acquire CT-based datasets. Plans were optimized for adequate HR-CTV D90 coverage while minimizing D2cm 3 doses to bladder, rectum, sigmoid, and bowel. EQD2 values (α/β = 3 for OARs; 10 for HR-CTV) were compared. Five retrospective cases were replanned using the novel RTA. Point A was redefined as 2cm superior along the tandem from the cervical os and 2cm lateral perpendicular to the tandem axis. Results: For patient 1, the novel RTA reduced average daily D2cm 3 by 0.54Gy (rectum), 0.78Gy (bladder), and 0.18Gy (sigmoid), with cumulative EQD2 reductions of 2.23Gy, 4.88Gy, and 1.05Gy, respectively. Patient 2 showed daily reductions of 0.52Gy (rectum) and 0.44Gy (bladder), with EQD2 decreases of 3.20Gy and 4.55Gy. HR-CTV EQD2 increased by 1.67Gy. Retrospective plans demonstrated consistent reductions in OAR doses. Conclusion: The novel RTA demonstrated favorable dosimetric trends for OAR sparing while maintaining target coverage in cervical HDR brachytherapy. The revised Point A definition provides a preliminary framework for anatomically consistent dose reporting in flexible tandem configurations.
- 22 June 2026
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 25
Open AccessA Novel Adjustable Tandem and Ring Applicator for Improved Dosimetry in Cervical Cancer HDR Brachytherapy
Introduction: Cervical cancer brachytherapy requires highly conformal dose delivery while minimizing radiation exposure to surrounding organs at risk. However, conventional tandem and ring applicators are limited by fixed geometry that may not optimally accommodate patient-specific anatomy. The purpose of this work was to evaluate the dosimetric performance of a novel tandem and ring applicator (RTA) featuring adjustable tandem translation relative to the ring, intended to improve organ-at-risk (OAR) sparing while preserving target coverage in high-dose-rate (HDR) brachytherapy for cervical cancer. Methods and Materials: A novel RTA allowing linear tandem translation within the ring plane was developed to enable patient-specific alignment without altering ring position. Two cervical cancer patients treated with external beam radiotherapy (45Gy/25 fractions) followed by HDR brachytherapy (27.5Gy/5 fractions) were analyzed. Conventional and novel RTAs were sequentially applied to acquire CT-based datasets. Plans were optimized for adequate HR-CTV D90 coverage while minimizing D2cm 3 doses to bladder, rectum, sigmoid, and bowel. EQD2 values (α/β = 3 for OARs; 10 for HR-CTV) were compared. Five retrospective cases were replanned using the novel RTA. Point A was redefined as 2cm superior along the tandem from the cervical os and 2cm lateral perpendicular to the tandem axis. Results: For patient 1, the novel RTA reduced average daily D2cm 3 by 0.54Gy (rectum), 0.78Gy (bladder), and 0.18Gy (sigmoid), with cumulative EQD2 reductions of 2.23Gy, 4.88Gy, and 1.05Gy, respectively. Patient 2 showed daily reductions of 0.52Gy (rectum) and 0.44Gy (bladder), with EQD2 decreases of 3.20Gy and 4.55Gy. HR-CTV EQD2 increased by 1.67Gy. Retrospective plans demonstrated consistent reductions in OAR doses. Conclusion: The novel RTA demonstrated favorable dosimetric trends for OAR sparing while maintaining target coverage in cervical HDR brachytherapy. The revised Point A definition provides a preliminary framework for anatomically consistent dose reporting in flexible tandem configurations.
- 23 August 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , S20
PPP03 Presentation Time: 4:18 PM
- 23 August 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , S20
PPP03 Presentation Time: 4:18 PM
- 23 August 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , S18-S19
MPP07 Presentation Time: 4:54 PM
- 23 August 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , S18-S19
MPP07 Presentation Time: 4:54 PM
- 23 August 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , S49-S50
GSOR01 Presentation Time: 11:30 AM
- 23 August 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , S49-S50
GSOR01 Presentation Time: 11:30 AM
- 21 August 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (6) , 931-939
Intraoperative low-dose rate brachytherapy as an adjunct to surgery for marginally resectable rectal and recurrent anorectal carcinomas
- 21 August 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (6) , 931-939
Intraoperative low-dose rate brachytherapy as an adjunct to surgery for marginally resectable rectal and recurrent anorectal carcinomas
- 23 March 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 207, 110866
Evaluating the prognostic significance of artificial intelligence-delineated gross tumor volume and prostate volume measurements for prostate radiotherapy
- 23 March 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 207, 110866
Evaluating the prognostic significance of artificial intelligence-delineated gross tumor volume and prostate volume measurements for prostate radiotherapy
- Open Access
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 17 (1) , 43-53
Skin marker for MR-only surface high-dose-rate brachytherapy
Purpose: Recent advances in surface high-dose-rate (HDR) brachytherapy imaging indicate that flap applicators, human skin, and fibromatosis can be visualized using MRI. Complete MR-only surface brachytherapy workflows would require skin marker identification to define clinical target edges....
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 17 (1) , 43-53
Open AccessSkin marker for MR-only surface high-dose-rate brachytherapy
Purpose: Recent advances in surface high-dose-rate (HDR) brachytherapy imaging indicate that flap applicators, human skin, and fibromatosis can be visualized using MRI. Complete MR-only surface brachytherapy workflows would require skin marker identification to define clinical target edges....
- 25 October 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (6) , S141-S142
PO0418
- 27 September 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 120 (2) , e579-e580
Prostate Salvage Brachytherapy Utilization and Efficacy over Two Decades at a Single Institution
- 27 September 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 120 (2) , e579-e580
Prostate Salvage Brachytherapy Utilization and Efficacy over Two Decades at a Single Institution
- 27 September 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 120 (2) , S110-S111
AAPM GEC-ESTRO Task Group 342: An Update on Image-Guided Robotic Brachytherapy
- 27 September 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 120 (2) , S110-S111
AAPM GEC-ESTRO Task Group 342: An Update on Image-Guided Robotic Brachytherapy